Clinical Trial Detail

NCT ID NCT04155580
Title A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astex Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

ASTX-660

ASTX-660 + ASTX727

Age Groups: adult senior

No variant requirements are available.